The leaders of SIGLA SCIENCES have decades of experience in pharma, biotech, and diagnostics, and have worked on dozens of product launches in oncology, specialty, and rare disease areas. Our team has also helped companies shape cross-portfolio marketing strategies, build commercial revenue forecasts, develop in-depth policy impact assessments, and create compelling payer value propositions for specialty products.
We understand that the strategies and tactics that previously led to blockbuster products are insufficient to guarantee access, market reach, and a strong value proposition in today's more challenging and sophisticated payer and provider landscape.
With Specialty & Oncology products representing >50% of the global development pipeline, we have Senior Partners with 25+ years specialty experience from development from launch through life-cycle management.
Our leaders have defined the RWE approaches for several companies—Big Pharma and small biotech alike. We are able to balance business and budget needs with the clinical and scientific expertise to optimize ROI for any size product or portfolio.
We’ve worked with commercial and proprietary Big Data, whether clinical or claims, and have expertise to help you make efficient, economical, and smarter data purchasing decisions, as well as how to leverage your and others’ data assets to drive business.
Members of our team have led the development and pull-through of value-based care strategies, including risk sharing/ outcomes-based contracting, since before these concepts were widespread.
We have one of the broadest networks spanning biopharma, clinical KOLs and academic medicine, diagnostics, biotech VC and investment, patient advocacy, and Washington, DC “insiders” in health policy, and we leverage these for you.
From traditional pricing and contracting approaches to innovative distribution channels and advocacy/policy plays, we not only know how to execute on any market access tactic, but we developed many of the tactics current in play for major life sciences companies.
Payer Value Proposition & Payer Story Development
Health Economics & Outcomes Research (HEOR)
Inflation Reduction Act & Impact to Pharma/Biotech
Value-Based / Outcomes-Based Contracting Policy
Financial Modeling / Scoring
Indication-Based Pricing
P&T/Pharmacist KOL engagement
Enhancing Oncology Model (EOM) & Oncology Care Model (OCM)
VA & DOD Contracting
Alternative Payment Models (APM)
Employer Strategies
MACRA and MIPS Organized Customer / IDN strategies
340B and DSH Payer Value Proposition
Institute for Clinical and Economic Review (ICER)
QALY and QALY Alternatives
NCCN and other Guidelines/Compendium orgs
ASP / Part B Pricing
Clinical Pathways organizations
Part B vs. Part D distribution and switching
NICE & European HTAs
CMMI and Medicare Demonstration Projects
Oncology (Solid Tumors & Malignant Heme)
Blood Disorders & Hematology
Immunology
CAR-T Therapeutics
Ophthalmology
Immuno-oncology therapies
Transplant (Solid Organ and Bone Marrow)
Cardiology
Diabetes
Oncology Supportive Care
Febrile Neutropenia
Gene Therapies
Rare and Orphan Diseases
Pain Management
Migraine
Psychiatric Therapies (Drug & Non-Drug Interventions)
Pharmaceutical Psychedelics
Women's Health and Fertility
Digital Health / Digital Therapeutics
"We are always excited to work with the team at Sigla because of their ability to help us tell strong stories to payers that are evidence-based and help us with our forecast access challenges bringing a higher cost drug to market. They really understand the landscape."
"The Sigla team understands the dynamics of an early stage company that is trying to position itself in the market while achieving success clinically and commercially; this is invaluable consulting expertise for leadership at our stage."
"Sigla has worked on, and in some cases helped build, the influential information products that impact oncology access such as NCCN Guidelines. They know what's realistic and what's practical in terms of getting things done and reaching market access goals."
"This team is at the future cutting-edge of what it will take for oncology products to be successful given the challenges of the market access landscape today. They are implementing tactics that others are not yet imagining."
"The market insights we got from this dashboard contained information we could not get from any other source. This was by far more cost efficient and more valuable than many other options."
"No team knows value based contracting better than this team. Others can propose ideas—but Sigla can go from the strategy through to the actual technology and data deployment and analytics."
